Navigation Links
Advanced Life Sciences Enters Into Definitive Securities Purchase Agreements for $20 Million with New and Existing Institutional Investors
Date:12/11/2007

cial Group LLLP and CRT Capital Group LLC acting as co- placement agents in the transaction.

This news release is not an offer to sell or the solicitation of an offer to buy any securities of the Company.

About Advanced Life Sciences

Advanced Life Sciences is a biopharmaceutical company engaged in the discovery, development and commercialization of novel drugs in the therapeutic areas of infection, cancer and inflammation. The Company's lead candidate, cethromycin, is a novel once-a-day oral antibiotic in late-stage development for the treatment of respiratory tract infections including CAP. For more information, please visit us on the web at http://www.advancedlifesciences.com.

Any statements contained in this presentation that relate to future plans, events or performance are forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. These forward-looking statements are subject to a number of risks and uncertainties that could cause actual results to differ materially from those described in the forward- looking statements.

These risks and uncertainties include, among others, those relating to technology and product development, market acceptance, government regulation and regulatory approval processes, intellectual property rights and litigation, dependence on collaborative relationships, ability to obtain financing, competitive products, industry trends and other risks identified in Advanced Life Sciences' filings with the Securities and Exchange Commission. Advanced Life Sciences undertakes no obligation to update or alter these forward-looking statements as a result of new information, future events or otherwise.


'/>"/>
SOURCE Advanced Life Sciences Holdings, Inc.
Copyright©2007 PR Newswire.
All rights reserved

Page: 1 2

Related biology technology :

1. Dendreon Announces Publication of Phase 1 Study Highlighting Immunologic and Clinical Activity of Lapuleucel-T (Neuvenge(R)) in Advanced Breast Cancer Patients
2. Advanced Life Sciences Announces Receipt of Nasdaq Staff Letter
3. Advanced Cell Technology Announces Proposed Financing
4. YM BIOSCIENCES, EUROPEAN PARTNER, ONCOSCIENCE AG, ANNOUNCES INITIATION OF ADVANCED NIMOTUZUMAB TRIALS IN ADULT GLIOMA AND PANCREATIC CANCER
5. Advanced Cell Technologys Dr. Robert Lanza Makes List of 100 Most Inspiring People in the Life-Sciences Industry
6. Advanced Life Sciences to Present at 2007 UBS Global Life Sciences Conference
7. CeloNova BioSciences Announces Worlds First Line of Fully Color-Coded Embolic Particles at CIRSE: Embozene(TM) Color-Advanced Microspheres
8. Edwards Lifesciences Grants UC Irvine $5 Million to Establish the Edwards Lifesciences Center for Advanced Cardiovascular Technology
9. Advanced Bionics Deploys CEVA-TeakLite(TM) DSP Core to Enhance Its Harmony(TM) HiResolution(R) Bionic Ear System
10. NIH Announces Advanced Cell Technologys Single Cell Embryo Biopsy Technique as a Means to Derive Embryonic Stem Cells to be Considered for Federal Funding
11. Cell Therapeutics, Inc. (CTI) Receives SPA Approval from FDA and Launches Gender-Specific Phase III Trial for Advanced Non-Small Cell Lung Cancer
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:6/30/2015)... ... June 30, 2015 , ... Students and faculty from ... first half of “Integrative Biotechnology,” an applied biotechnology course team-taught by faculty members ... course combines students from both universities and is taught on both continents. , ...
(Date:6/30/2015)... , June 30, 2015  NASA astronaut Kjell ... next month on his first mission to the International ... from 8 to 9 a.m. EDT Tuesday, July 7. ... in Star City, Russia . The interviews ... NASA Television highlighting his mission training. To schedule ...
(Date:6/30/2015)... ... 30, 2015 , ... uBiome and OpenBiome Partner for Microbiome ... fecal microbiota transplantation in C. difficile patients. , SAN FRANCISCO, uBiome and OpenBiome ... microbiota transplantation (FMT) as a treatment for Clostridium difficile infections (C. diff). , ...
(Date:6/30/2015)... ... June 30, 2015 , ... The maximum number of shares ... outstanding common shares (including shares of unvested restricted stock). On June 29, 2015, the ... price of Cryo-Cell’s shares reported on the OTCBB was $2.29 per share. , The ...
Breaking Biology Technology:Rivier University and Beijing City University Academic and Cultural Exchanges Begin 2NASA Astronaut Preps for First Space Station Mission, Available for Media Interviews 2uBiome and OpenBiome Partner for Microbiome Study in FMT Patients 2uBiome and OpenBiome Partner for Microbiome Study in FMT Patients 3Cryo-Cell Commences Tender Offer to Purchase its Common Stock, Up to 750,000 Shares at $3.25 per Share 2Cryo-Cell Commences Tender Offer to Purchase its Common Stock, Up to 750,000 Shares at $3.25 per Share 3
... Sagent Pharmaceuticals, Inc.,a privately-held specialty pharmaceutical company, today ... Red Cross to assist the victims,of Monday,s earthquake ... the global community, we were saddened by the ... said Jeffrey M. Yordon,chief executive officer, founder, and ...
... NANJING, China, May 14 Simcere Pharmaceutical,Group (NYSE: SCR ... manufacturer of the patented anti-cancer biotech,product Endu in China, today ... investor conferences:, * Brean Murray Carret & ... Waldorf-Astoria in New York on Monday, May 19, 2008 ...
... 1c Study Demonstrates Dose-dependent Activity of Antidote Component, ... today announced,the Journal of Thrombosis and Haemostasis, the ... Haemostasis, has published the,Phase 1c clinical results of ... system comprised of an aptamer-based anticoagulant,RB006, and its ...
Cached Biology Technology:Simcere Pharmaceutical Group to Participate in Upcoming Investor Conferences in New York 2Regado Biosciences' REG1 Anticoagulation System Study Results Published in the Journal of Thrombosis and Haemostasis 2Regado Biosciences' REG1 Anticoagulation System Study Results Published in the Journal of Thrombosis and Haemostasis 3Regado Biosciences' REG1 Anticoagulation System Study Results Published in the Journal of Thrombosis and Haemostasis 4
(Date:6/23/2015)... June 23, 2015   MedNet Solutions , ... the entire spectrum of clinical research, is pleased ... ™ , the company,s intuitive, flexible and affordable ... Silver 2015 Stevie® Award by the American ... Services Website category.  The American Business Awards are ...
(Date:6/18/2015)... , June 18, 2015 NXT-ID, Inc. (NASDAQ: ... focused on the growing mobile commerce market announces that its ... segment on "Money on the Mark", scheduled to air on ... June 20 th . The broadcast ... from 7:00 to 8:00pm EST. NXT-ID, Inc.,s CEO Gino ...
(Date:6/16/2015)... /CNW Telbec/ - handyem Inc. and FlowMetric Diagnostics ... of handyem,s HPC-150 portable flow cytometer within FlowMetric ... unprecedented model of mobile laboratory platform is presented ... Pennsylvania Convention Center, ... to 18 th 2015.  By virtue of ...
Breaking Biology News(10 mins):MedNet Solutions' iMedNet eClinical Wins Silver Stevie Award 2NXT-ID, Inc.'s CEO Gino Pereira Talks About the Wocket Smart Wallet on WABC Radio, New York City, June 20th 2NXT-ID, Inc.'s CEO Gino Pereira Talks About the Wocket Smart Wallet on WABC Radio, New York City, June 20th 3handyem and FlowMetric Diagnostics announce their partnership in the development of Flow Cytometry- Based Solutions in diagnostic capabilities 2handyem and FlowMetric Diagnostics announce their partnership in the development of Flow Cytometry- Based Solutions in diagnostic capabilities 3
... JUPITER, FL, April 10, 2010 For years, scientists ... of producing specific proteins through RNA transcription. Now, research led ... Institute has shown DNA can also act to fine-tune the ... These new findings may make it possible to design therapies ...
... roughly six million Americans, yet treatment consists of either a ... the heart. This is unacceptable to Roberto Bolli, MD, Chief ... Louisville in Louisville, Ky., which is why he is on ... for all who must cope with the limitations of a ...
... falls in a virtual reality forest, will anyone hear an environmental ... who cut down the make-believe redwood. New findings from Stanford ... forest and told to saw through a towering sequoia until it ... real world than people who only imagined what it,s like to ...
Cached Biology News:Scripps Research scientists uncover new DNA role in modifying gene function 2Scripps Research scientists uncover new DNA role in modifying gene function 3Roberto Bolli discusses cardiac stem cell treatment for heart failure at Cannon Lecture 2Roberto Bolli discusses cardiac stem cell treatment for heart failure at Cannon Lecture 3Stanford's virtual reality lab focuses on conservation 2Stanford's virtual reality lab focuses on conservation 3